Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress

NovartisThe Novartis Foundation and its partners will highlight progress in efforts toward accelerating the elimination of leprosy at the 19th International Leprosy Congress (ILC) held in Beijing, China from September 18 - 21, 2016. Updates in 11 abstracts on four Novartis Foundation-supported leprosy initiatives in low- and middle-income countries will be showcased in scientific sessions.

Abstracts presented at the ILC demonstrate progress on the key programs under the Novartis Foundation strategy toward zero transmission of leprosy. The strategy was launched in 2014 to prioritize early detection and treatment, contact tracing and preventative treatment, strengthening of surveillance systems to become action-oriented and developing tools for faster and earlier diagnosis.

"The ILC is a great opportunity to present results of our leprosy strategy gaining momentum, share learnings, and highlight the research we support on diagnostic development and epidemiological modelling, which can contribute to the design of future strategies to finally make leprosy history. I am particularly pleased to share emerging evidence on our multi-country Leprosy Post-Exposure Prophylaxis (LPEP) program, which at mid-point is already demonstrating the feasibility of integrating its strategy of contact tracing and preventative therapy in national control programs," said Dr. Ann Aerts, Head of the Novartis Foundation.

Novartis Foundation-sponsored projects presented at ILC scientific sessions:

  • Cambodia Retrospective Active Case Finding project: recommendations for targeting high-priority districts in phase 2 (Abstract ILC4.2-052/8.5, September 19, 13:30 CST)
  • Accuracy of the Leprosy Alert Response Network and Surveillance (LEARNS) System of the Novartis Foundation and Philippine Department of Health - National Leprosy Control Program (ILC4.2-025/8.3, September 19, 13:30 CST)
  • Criteria for a developing a PCR test (Abstract 47.1, September 20, 10:30 CST)
  • Emerging evidence from the Leprosy Post-Exposure Prophylaxis project (Abstract ILC4.3-012/17.1, September 20, 13:30 CST)
  • An interim report on the operational feasibility of leprosy post-exposure prophylaxis in Dadra and Nagar Haveli, India (Abstract ILC4.3-014/17.2, September 20, 13:30 CST)
  • Comparison of implementation aspects of Leprosy Post-Exposure Prophylaxis in India, Nepal and Indonesia (Abstract ILC4.3-022/17.3, September 20, 13:30 CST)
  • Negotiating and implementing the Leprosy Post-Exposure Prophylaxis project in the centralized health service of the Union of Myanmar (Abstract ILC4.3-011/17.4, September 20, 13:30 CST)
  • LPEP and implementation experiences from Nepal (Abstract ILC4.3-009/17.5, September 20, 13:30 CST)
  • Modeling the long term impact of additional interventions on the new case detection rate of leprosy in three endemic countries and regions (Abstract ILC4.3-007/17.6, September 20, 13:30 CST)
  • Delivering leprosy post-exposure prophylaxis in a remote area: a case of Lingat Village, Maluku, Indonesia (Abstract ILC4.3-017/25.6, September 20, 15:30 CST)
  • Distribution of leprosy post-exposure prophylaxis through extended contact-tracing with self-screening approach in Sumenep District, Indonesia (Abstract ILC4.3-018/25.8, September 20, 15:30 CST)

"This year we commemorate 30 years of Novartis Foundation commitment in the fight against leprosy," reflected Ann Aerts; "therefore the ILC is timely to review the progress we are making together with our partners toward zero transmission of leprosy. It is also a fitting time to look ahead and envision a coalition to bring the anti-leprosy community together to go the last mile in the fight against leprosy."

Novartis and the Novartis Foundation have a long-term commitment to leprosy treatment and control. Since 2000, Novartis has donated more than 56 million blister packs valued at approximately USD 90 million through the World Health Organization (WHO), helping to treat more than six million leprosy patients worldwide.

About the Novartis Foundation
The Novartis Foundation is a philanthropic organization pioneering innovative healthcare models that can have a transformational impact on the health of the poorest populations. We work hand-in-hand with our local and global partners to catalyze scalable and sustainable healthcare models to improve access and health outcomes, and to accelerate efforts to eliminate leprosy and malaria by focusing on interventions that aim to interrupt transmission. Everything we do is grounded in evidence and innovation, and our work is a continuous cycle of evaluation, adaptation and application. In 2015, the operational budget for the foundation was CHF 12 million and our programs reached 4.5 million people.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Roche's first FDA-approved tumour-agnostic medicin…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with R...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...